Internal Medicine, Endocrinology, Diabetes, & Metabolism · Arvada, CO
NPI
1518092972
Since 2007
Specialty
Internal Medicine, Endocrinology, Diabetes, & Metabolism
Code 207RE0101X
Group practices
2
Medicare group memberships
Hospitals
3
Hospital affiliations
15389 W 91st Dr Ste 200
Arvada, CO, 80007
Phone (303) 403-7933
Groups this clinician bills Medicare through
Medicare paid, 2024
$48K
770 services
Medicare patients, 2024
238
Average age 73
Drug cost, 2024
$1.4M
3,322 prescriptions
Company payments, 2025
$36K
From 12 companies
Procedures and visits billed to Original Medicare, 2024
In 2024, the most common Medicare service billed by Michelle K Cassara was code G2211 (visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's), 369 times for 219 patients. In total Michelle K Cassara billed 770 services in 7 codes, and Medicare paid $48K.
Official US government data: the national provider registry and Medicare enrollment records, linked by NPI. Last update of this record: 2025-01-30.
| Code | Setting | Services | Patients | Paid per service | Medicare paid |
|---|---|---|---|---|---|
| G2211 Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's | Office | 369 | 219 | $12.50 | $4,614 |
| 99214 Office E&M - Established | Office | 193 | 146 | $88.09 | $17K |
| 99215 Office E&M - Established | Office | 162 | 74 | $143.17 | $23K |
| 99213 Office E&M - Established | Office | 39 | 38 | $67.90 | $2,648 |
By year: 2022 $40K for 372 services; 2023 $41K for 388 services; 2024 $48K for 770 services.
Medicare prescription drug claims, 2024
In 2024, the drug Michelle K Cassara prescribed most often to Medicare patients was Levothyroxine Sodium, with 514 prescriptions and refills. In total Michelle K Cassara wrote 3,322 Medicare prescriptions that cost $1.4M.
| Drug | Claims | 30-day fills | Patients | Cost |
|---|---|---|---|---|
| Levothyroxine Sodium Generic | 514 | 1,443 | 147 | $5,322 |
| Synthroid Levothyroxine Sodium | 213 | 573 | 56 | $23K |
| Metformin Hcl Generic | 159 | 453 | 50 | $1,437 |
| Ozempic Semaglutide | 155 | 254 | 36 | $244K |
| Mounjaro Tirzepatide | 153 | 167 | 21 | $174K |
| Liothyronine Sodium Generic | 139 | 399 | 42 | $5,180 |
| Lantus Solostar Insulin Glargine,hum.Rec.Anlog | 109 | 270 | 36 | $20K |
| Ultra-Fine Mini Pen Needle Pen Needle, Diabetic | 86 | 194 | 33 | $7,329 |
| Trulicity Dulaglutide | 79 | 113 | 20 | $109K |
| Jardiance Empagliflozin | 73 | 178 | 25 | $104K |
| Metformin Hcl Er Metformin Hcl | 73 | 210 | 23 | $1,335 |
| Humalog Insulin Lispro | 66 | 156 | 25 | $27K |
| Humalog Kwikpen U-100 Insulin Lispro | 60 | 153 | 26 | $21K |
| Tresiba Flextouch U-200 Insulin Degludec | 44 | 99 | 13 | $65K |
| Ultra-Fine Short Pen Needle Pen Needle, Diabetic | 43 | 87 | 14 | $4,478 |
Brand drugs: 1,848 claims; generic drugs: 1,159 claims.
Money and other things of value reported by the companies
In 2025, drug and medical device companies paid Michelle K Cassara $36K ($36K in general payments such as food, travel and fees) from 12 companies. The largest payer was Novo Nordisk Inc with $36K.
| Company | Payments | Amount |
|---|---|---|
| Novo Nordisk Inc NVO | 30 | $36K |
| Ascendis Pharma Endocrinology Inc ASND | 2 | $140 |
| Madrigal Pharmaceuticals MDGL | 1 | $135 |
| Medtronic, Inc. MDT | 1 | $83.78 |
| Dexcom, Inc. DXCM | 2 | $43.2 |
| Beta Bionics, Inc. BBNX | 2 | $40.77 |
| CeQur Corporation | 1 | $32.46 |
| Insulet Corporation PODD | 1 | $30.85 |
| Abbott Laboratories ABT | 1 | $26.82 |
| Tandem Diabetes Care, Inc. TNDM | 1 | $26.24 |
Official US government data on Original Medicare services, Medicare prescription drug plans and the payments drug and device companies must report. Services with fewer than 11 patients and drugs with fewer than 11 claims are not published. Procedure codes are shown by number with their public category.